Viridian Therapeutics
Business Services · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
221 Crescent St Ste 103A, Waltham, Massa...Phone Number
(617) 272-4600Website
www.viridiantherapeutics.comRevenue
$71.1 MillionStock Symbol
VRDNIndustry
ZI Rank: 2
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
3
1
2
2
2
2
About Viridian Therapeutics
Viridian Therapeutics is advancing new treatments for patients suffering from serious diseases but underserved by todays therapies. Viridians patient-centric model of innovation leverages proven biology and technology to efficiently allocate research and development resources, while addressing strategic gaps related to access, delivery, quality of life, and efficacy in therapeutic areas of focus.Explore more
Viridian Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Viridian Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Viridian Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Viridian Therapeutics launches new products
Viridian Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Viridian Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Viridian Therapeutics
Earning: See what the market has to say on Viridian Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if Viridian Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Viridian Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Viridian Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Viridian Therapeutics
Compare insights from companies similar to Viridian Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Viridian Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Viridian Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Viridian Therapeutics.
Viridian Therapeutics financials insights
Gather financial insights about Viridian Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Debt
$75M
Viridian Therapeutics Tech Stack
A closer look at the technologies used by Viridian Therapeutics
See more technologies
Most Recent Scoops
Open Position
Earnings
Viridian Therapeutics has announced that elegrobart (veli), which has the potential to be the first subcutaneous auto-injector for thyroid eye disease (TED) patients, is on track for a Biologics License Application (BLA) submission in Q1 2027, supported by two successful Phase III pivotal trials in active and chronic TED, with both Q4W and Q8W dosing regimens being advanced.
Product Development, Pharmaceuticals, Clinical Operations
Earnings
Viridian Therapeutics has announced that elegrobart's Q4W dosing regimen demonstrated strong responses in both proptosis and diplopia, while the Q8W regimen demonstrated strong responses in proptosis and is considered suitable for patients where diplopia is not the primary complaint, with both regimens being advanced toward a BLA submission targeted for Q1 2027.
Medical Research, Pharmaceuticals
Project
Viridian Therapeutics has announced that Lumvoa demonstrated rapid and durable improvements in proptosis in active TED patients, with 70% achieving a proptosis response at week 15,14 times the placebo response rate and 71% of those patients maintaining their response through week 52, which was 40 weeks after their final dose.
Medical Research, Pharmaceuticals
Project
Pharmaceuticals, Clinical Operations
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Viridian Therapeutics
Sign Up For FreeTo access detailed company insights
Viridian Therapeutics is advancing new treatments for patients suffering from serious diseases but underserved by todays therapies. Viridians patient-centric model of innovation leverages proven biology and technology to efficiently allocate research and development resources, while addressing strategic gaps related to access, delivery, quality of... Read More
